clinical trial · NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Multiple MyelomaCevostamabPomalidomideDexamethasoneDaratumumabElotuzumabCarfilzomib
brief summary
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
started
Jun 23, 2026
primary completion
Oct 31, 2028
completion
Jan 31, 2033
last updated
Aug 14, 2026
official title
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol